Literature DB >> 11274640

Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma.

T Shimonishi1, K Miyazaki, N Kono, H Sabit, K Tuneyama, K Harada, J Hirabayashi, K Kasai, Y Nakanuma.   

Abstract

Galectins, a family of beta-galactoside-binding animal lectins, might be involved in tumor progression. In this study, the expression patterns of galectin-1 and -3 were examined immunohistochemically in intrahepatic cholangiocarcinoma (ICC), with emphasis on its development and progression as well as its histopathologic features, by use of samples of normal intrahepatic bile duct (n = 20), biliary epithelial dysplasia (n = 15), ICC (n = 40), and a cholangiocarcinoma cell line, CCKS1. In normal intrahepatic bile ducts, galectin-3 was constitutively but weakly expressed, whereas galectin-1 was not expressed. In hepatolithiasis, biliary epithelial dysplasia was strongly positive for galectin-3 but negative for galectin-1. Galectin-3 was frequently and strongly expressed in the cytoplasm of well-differentiated ICCs, and its expression was significantly decreased and less intense or even absent in poorly differentiated ICCs. Galectin-1 was expressed in carcinoma cells in ICC, and its incidence and extent were correlated with histologic dedifferentiation of ICC. Proliferative cell nuclear antigen (PCNA) labeling index (LI) was higher in ICC cases positive for galectin-1 than in those that were negative. Galectin-1 was strongly expressed in cancerous stroma of ICC, and this stromal expression was related to histologic dedifferentiation of ICC. In the carcinoma cell line CCKS1, galectin-1 and -3 were expressed in the cytoplasm of carcinoma cells, and galectin-1 was additionally detected in the culture medium. These results suggest that galectin-1 was newly expressed on carcinoma cells of ICC, and its overexpression seems to be associated with neoplastic progression and proliferative activities, and the expression of galectin-1 in cancerous stroma may also be related to the progression of ICC. Galectin-3 expression in epithelial cells is up-regulated in the preneoplastic and early neoplastic stages of ICC, although galectin-3 tends to disappear at later stages of ICC. HUM PATHOL 32:302-310. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274640     DOI: 10.1053/hupa.2001.22767

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  25 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.

Authors:  Sibel Bektas; Burak Bahadir; Bulent Hamdi Ucan; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

3.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

4.  Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.

Authors:  Ling Li; Klaus Piontek; Masaharu Ishida; Michel Fausther; Jonathan A Dranoff; Rongdang Fu; Esteban Mezey; Stephen J Gould; Francis K Fordjour; Stephen J Meltzer; Alphonse E Sirica; Florin M Selaru
Journal:  Hepatology       Date:  2016-08-29       Impact factor: 17.425

5.  Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease.

Authors:  M Butscheid; P Hauptvogel; P Fritz; U Klotz; D M Alscher
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

6.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

Authors:  Shusaku Ohira; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Yoh Zen; Kumiko Isse; Kazuto Kozaka; Akira Ishikawa; Koji Oda; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

7.  Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness.

Authors:  Daniela Spano; Roberta Russo; Vittorio Di Maso; Natalia Rosso; Luigi M Terracciano; Massimo Roncalli; Luigi Tornillo; Mario Capasso; Claudio Tiribelli; Achille Iolascon
Journal:  Mol Med       Date:  2009-12-21       Impact factor: 6.354

8.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

Review 9.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

10.  Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.

Authors:  Yijun Xu; Mingchen Zhu; Shuhong Zhang; Hui Liu; Tao Li; Chengyong Qin
Journal:  Pathol Oncol Res       Date:  2009-09-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.